The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions

Nicholas D. Stafford, L. T. Condon, M. J C Rogers, A. W. Macdonald, Stephen Atkin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The role of chemotherapy in squamous cell carcinoma of the larynx has not been clearly defined. Whilst toxic chemotherapy regimes may confer a marginal improvement in survival, surgery and radiotherapy remain the mainstay of treatment. Somatostatin is a naturally occurring peptide, which exerts antiproliferative and antiangiogenic effects via five membrane-bound receptor subtypes. The expression of somatostatin receptor subtypes (SSTRs) 1 and 2 was studied in benign, pre-malignant and malignant laryngeal specimens. Epithelial expression of SSTR1 was detected in 4/6 (67%) Reinke's oedema, 5/6 (83%) pre-malignant and 8/12 (67%) malignant specimens, with virtually no stromal or vascular expression. High levels of epithelial SSTR2 expression were noted in all Reinke's oedema specimens, compared with low-to-moderate levels in only 2/6 (33%) pre-malignant and 3/12 (25%) malignant specimens (P < 0.01). This 'loss' of epithelial SSTR2 expression may provide a growth advantage in pre-malignant and malignant laryngeal lesions. Vascular expression of SSTR2 was ubiquitous in all groups, with scant stromal expression. Overall, most (>80%) pre-malignant and malignant laryngeal specimens expressed at least one of the two SSTR subtypes studied. Somatostatin analogues may have a therapeutic role in squamous cell carcinoma of the larynx.

Original languageEnglish
Pages (from-to)314-319
Number of pages6
JournalClinical Otolaryngology and Allied Sciences
Volume28
Issue number4
DOIs
Publication statusPublished - Aug 2003
Externally publishedYes

Fingerprint

Larynx
Somatostatin
Squamous Cell Carcinoma
Edema
Drug Therapy
Somatostatin Receptors
Poisons
Blood Vessels
Radiotherapy
Peptides
Membranes
Therapeutics
somatostatin receptor 2
somatostatin receptor type 1

Keywords

  • Immunohistochemistry
  • Larynx pre-malignant
  • Reinke's oedema
  • Somatostatin
  • Somatostatin receptors
  • Squamous cell carcinoma
  • SRIF (somatotroph release inhibiting factor)

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions. / Stafford, Nicholas D.; Condon, L. T.; Rogers, M. J C; Macdonald, A. W.; Atkin, Stephen.

In: Clinical Otolaryngology and Allied Sciences, Vol. 28, No. 4, 08.2003, p. 314-319.

Research output: Contribution to journalArticle

Stafford, Nicholas D. ; Condon, L. T. ; Rogers, M. J C ; Macdonald, A. W. ; Atkin, Stephen. / The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions. In: Clinical Otolaryngology and Allied Sciences. 2003 ; Vol. 28, No. 4. pp. 314-319.
@article{5b31774cd34e479d87297351c4f47a17,
title = "The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions",
abstract = "The role of chemotherapy in squamous cell carcinoma of the larynx has not been clearly defined. Whilst toxic chemotherapy regimes may confer a marginal improvement in survival, surgery and radiotherapy remain the mainstay of treatment. Somatostatin is a naturally occurring peptide, which exerts antiproliferative and antiangiogenic effects via five membrane-bound receptor subtypes. The expression of somatostatin receptor subtypes (SSTRs) 1 and 2 was studied in benign, pre-malignant and malignant laryngeal specimens. Epithelial expression of SSTR1 was detected in 4/6 (67{\%}) Reinke's oedema, 5/6 (83{\%}) pre-malignant and 8/12 (67{\%}) malignant specimens, with virtually no stromal or vascular expression. High levels of epithelial SSTR2 expression were noted in all Reinke's oedema specimens, compared with low-to-moderate levels in only 2/6 (33{\%}) pre-malignant and 3/12 (25{\%}) malignant specimens (P < 0.01). This 'loss' of epithelial SSTR2 expression may provide a growth advantage in pre-malignant and malignant laryngeal lesions. Vascular expression of SSTR2 was ubiquitous in all groups, with scant stromal expression. Overall, most (>80{\%}) pre-malignant and malignant laryngeal specimens expressed at least one of the two SSTR subtypes studied. Somatostatin analogues may have a therapeutic role in squamous cell carcinoma of the larynx.",
keywords = "Immunohistochemistry, Larynx pre-malignant, Reinke's oedema, Somatostatin, Somatostatin receptors, Squamous cell carcinoma, SRIF (somatotroph release inhibiting factor)",
author = "Stafford, {Nicholas D.} and Condon, {L. T.} and Rogers, {M. J C} and Macdonald, {A. W.} and Stephen Atkin",
year = "2003",
month = "8",
doi = "10.1046/j.1365-2273.2003.00711.x",
language = "English",
volume = "28",
pages = "314--319",
journal = "Clinical Otolaryngology",
issn = "1749-4478",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions

AU - Stafford, Nicholas D.

AU - Condon, L. T.

AU - Rogers, M. J C

AU - Macdonald, A. W.

AU - Atkin, Stephen

PY - 2003/8

Y1 - 2003/8

N2 - The role of chemotherapy in squamous cell carcinoma of the larynx has not been clearly defined. Whilst toxic chemotherapy regimes may confer a marginal improvement in survival, surgery and radiotherapy remain the mainstay of treatment. Somatostatin is a naturally occurring peptide, which exerts antiproliferative and antiangiogenic effects via five membrane-bound receptor subtypes. The expression of somatostatin receptor subtypes (SSTRs) 1 and 2 was studied in benign, pre-malignant and malignant laryngeal specimens. Epithelial expression of SSTR1 was detected in 4/6 (67%) Reinke's oedema, 5/6 (83%) pre-malignant and 8/12 (67%) malignant specimens, with virtually no stromal or vascular expression. High levels of epithelial SSTR2 expression were noted in all Reinke's oedema specimens, compared with low-to-moderate levels in only 2/6 (33%) pre-malignant and 3/12 (25%) malignant specimens (P < 0.01). This 'loss' of epithelial SSTR2 expression may provide a growth advantage in pre-malignant and malignant laryngeal lesions. Vascular expression of SSTR2 was ubiquitous in all groups, with scant stromal expression. Overall, most (>80%) pre-malignant and malignant laryngeal specimens expressed at least one of the two SSTR subtypes studied. Somatostatin analogues may have a therapeutic role in squamous cell carcinoma of the larynx.

AB - The role of chemotherapy in squamous cell carcinoma of the larynx has not been clearly defined. Whilst toxic chemotherapy regimes may confer a marginal improvement in survival, surgery and radiotherapy remain the mainstay of treatment. Somatostatin is a naturally occurring peptide, which exerts antiproliferative and antiangiogenic effects via five membrane-bound receptor subtypes. The expression of somatostatin receptor subtypes (SSTRs) 1 and 2 was studied in benign, pre-malignant and malignant laryngeal specimens. Epithelial expression of SSTR1 was detected in 4/6 (67%) Reinke's oedema, 5/6 (83%) pre-malignant and 8/12 (67%) malignant specimens, with virtually no stromal or vascular expression. High levels of epithelial SSTR2 expression were noted in all Reinke's oedema specimens, compared with low-to-moderate levels in only 2/6 (33%) pre-malignant and 3/12 (25%) malignant specimens (P < 0.01). This 'loss' of epithelial SSTR2 expression may provide a growth advantage in pre-malignant and malignant laryngeal lesions. Vascular expression of SSTR2 was ubiquitous in all groups, with scant stromal expression. Overall, most (>80%) pre-malignant and malignant laryngeal specimens expressed at least one of the two SSTR subtypes studied. Somatostatin analogues may have a therapeutic role in squamous cell carcinoma of the larynx.

KW - Immunohistochemistry

KW - Larynx pre-malignant

KW - Reinke's oedema

KW - Somatostatin

KW - Somatostatin receptors

KW - Squamous cell carcinoma

KW - SRIF (somatotroph release inhibiting factor)

UR - http://www.scopus.com/inward/record.url?scp=0041529753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041529753&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2273.2003.00711.x

DO - 10.1046/j.1365-2273.2003.00711.x

M3 - Article

VL - 28

SP - 314

EP - 319

JO - Clinical Otolaryngology

JF - Clinical Otolaryngology

SN - 1749-4478

IS - 4

ER -